MSB 2022 - The road to commercialisation, page-1190

At the end of the day it's clear this process is complex. The science is nuanced. We haven't been given nearly enough information by the company to make an accurate guess at which way approval will go.

We are all just guessing. Everyone knows my thoughts on the matter - needs further trials, interesting stuff but lots of hurdles to overcome before efficacy is proven. This is purely based on my experience in the field, and I am by no means an expert.

Many here might not believe it, but I am not short this company, I am not financially involved at all.

The "downrampers" base their opinions on their own experiences, and the "uprampers" do the same.

I hope no one is basing their opinions on things they read here, or on Facebook, or on what ecool wrote. They should also take everything the company says with a grain of salt - look at the data yourself.

Look at the hurdles that previous biotech, previous stem cell companies have faltered at. And look at those companies' phase two trials, which are often very promising and groundbreaking.

DYOR.

If it were easy to "cure all diseases", we would've done it by now.

IMO. GLTAH